BioSpace News Archive

Drug Development

Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618

Deciphera Pharmaceuticals, Inc. announced the presentation today of updated data from its ongoing Phase 1 clinical trial of DCC-2618.

June 2, 2018
·
10 min read
Global Spirometer Market| Growth Analysis and Forecast| Technavio

Market research firm Technavio has announced the release of their latest report on the global spirometer market. This new report will provide expert market insights for the forecast period 2018-2022.

June 2, 2018
·
3 min read
BioForest

S.A.F.E. Project US Invests in Law Enforcement Training for Opioid Response

This week, justice and recovery professionals fighting the nation’s battle against the opioid epidemic have convened in Houston for the National Association of Drug Court Professionals (NADCP) annual conference.

June 2, 2018
·
2 min read
Genetown

New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

A new study published today in JAMA Oncology that explores new business models for funding drug development to treat pediatric cancers.

June 2, 2018
·
4 min read
Biotech Beach

Dendreon Publishes New Data in Clinical Cancer Research Correlating the Magnitude of Cytotoxic T Cell Response to PROVENGE® (sipuleucel-T) Treatment with Overall Survival

Dendreon Pharmaceuticals LLC announced publication of new data in Clinical Cancer Research, a journal of the American Association for Cancer Research.

June 2, 2018
·
5 min read
Drug Development

X4 Pharmaceuticals Reports Positive Clinical Data from Phase 2 Expansion Study of X4P-001-IO and Axitinib in Patients with Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals announced positive clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).

June 2, 2018
·
4 min read
Drug Development

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

New Novartis data from two long-term Treatment-free Remission (TFR) studies in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase (CP) will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

June 2, 2018
·
14 min read
Drug Development

Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting

AstraZeneca and MedImmune, its global biologics research and development arm presented results from the Phase III (‘1053’) clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell leukemia (HCL) who had received at least two prior lines of therapy.

June 2, 2018
·
10 min read
BioMidwest

NantOmics to Share Results of NantOmics Pharmacogenomics Test at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantOmics, LLC, will present results from the NantOmics pharmacogenomics test, an integrative panomic approach to pharmacogenomics screening, during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

June 2, 2018
·
2 min read
BioMidwest

NantOmics to Present Potential Treatment Options for SCLC Patients with Multiplexed Clinical Proteomic Testing at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantOmics, LLC will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer.

June 2, 2018
·
3 min read